Acumen Pharmaceuticals Inc

ABOS

Company Profile

  • Business description

    Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.

  • Contact

    1210-1220 Washington Street
    Suite 210
    NewtonMA02465
    USA

    T: +1 617 344-4190

    https://www.acumenpharm.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    52

Stocks News & Analysis

stocks

Netflix: A business that’s nearly flawless

Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks

Trump’s US dollar assault is fuelling CBA’s rise

A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.
stocks

Insignia Financial: Revised deal still attractive

The offer price is well above our fair value.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,000.001.40-0.02%
CAC 407,850.43106.021.37%
DAX 4024,240.82198.920.83%
Dow JONES (US)45,010.29507.851.14%
FTSE 1009,061.4937.680.42%
HKSE25,538.07408.041.62%
NASDAQ21,020.02127.330.61%
Nikkei 22541,729.02557.701.35%
NZX 50 Index12,822.3128.250.22%
S&P 5006,358.9149.290.78%
S&P/ASX 2008,734.302.90-0.03%
SSE Composite Index3,582.300.440.01%

Market Movers